Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab

被引：7

作者：

Ebrahimiadib, Nazanin ^{[1
]}

Lashay, Alireza ^{[1
]}

Riazi-Esfahani, Hamid ^{[1
]}

Jamali, Sepideh ^{[1
]}

Khodabandeh, Alireza ^{[1
]}

Zarei, Mohammad ^{[1
]}

Roohipoor, Ramak ^{[1
]}

Khojasteh, Hassan ^{[1
]}

Bazvand, Fatemeh ^{[1
]}

Ojani, Mina ^{[1
]}

Shahabinejad, Mojtaba ^{[1
]}

Yaseri, Mehdi

Modjtahedi, Bobeck S. ^{[2
,3
]}

Davoudi, Samaneh ^{[4
]}

Riazi-Esfahani, Mohammad ^{[5
]}

机构：

[1] Univ Tehran Med Sci, Farabi Eye Hosp, Eye Res Ctr, Qazvin Sq,South Kargar St, Tehran, Iran

[2] Southern Calif Permanente Med Grp, Dept Ophthalmol, Baldwin Pk, CA USA

[3] Kaiser Permanente Southern Calif, Eye Monitoring Ctr, Baldwin Pk, CA USA

[4] Univ Florida, Dept Ophthalmol, Gainesville, FL USA

[5] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA USA

来源：

OPHTHALMIC SURGERY LASERS & IMAGING RETINA | 2020年 / 51卷 / 03期

关键词：

DEGENERATION; INFLAMMATION; SAFETY;

D O I：

10.3928/23258160-20200228-03

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

BACKGROUND AND OBJECTIVE: To evaluate the efficacy of intravitreal ziv-aflibercept (IVZ) in patients with diabetic macular edema (DME) resistant to intravitreal bevacizumab (IVB). PATIENTS AND METHODS: This prospective study was conducted in patients with persistent DME. Patients were switched to IVZ no longer than 6 weeks after the last three consecutive monthly IVB treatments and monitored over a course of 12 weeks. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume on optical coherence tomography were compared. RESULTS: A total of 59 eyes (38 patients) were included. Mean BCVA improved from 0.84 to 0.71 IogMAR (P = .001) after first IVZ treatment and remained significant. In a subgroup analysis, this significance was observed only in the group with baseline visual acuity of less than 20/50. Mean CMT decreased from 479 mu m to 364 mu m (P = .004) after the first IVZ injections and remained significant. CONCLUSION: IVZ may be best reserved for patients with persistent DME after initial failure with bevacizumab, with less likelihood for anatomic or functional improvement in those with mild persistent DME.

引用

页码：145 / 151

页数：7

共 23 条

[1] Recommendations for analysis of repeated-measures designs: testing and correcting for sphericity and use of manova and mixed model analysis [J].

Armstrong, Richard A. .

OPHTHALMIC AND PHYSIOLOGICAL OPTICS, 2017, 37 (05) :585-593

[2] Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema [J].

Ashraf, Mohammed ;

El Kayal, Hassan ;

Souka, Ahmed A. R. .

OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2017, 48 (05) :399-405

[3] Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration [J].

Braimah, Imoro Zeba ;

Stewart, Michael ;

Videkar, Chetan ;

Dedhia, Chintan J. ;

Chhablani, Jay .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (09) :1201-1205

[4] Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment A Secondary Analysis of a Randomized Clinical Trial [J].

Bressler, Neil M. ;

Beaulieu, Wesley T. ;

Glassman, Adam R. ;

Blinder, Kevin J. ;

Bressler, Susan B. ;

Jampol, Lee M. ;

Melia, Michele ;

Wells, John A., III .

JAMA OPHTHALMOLOGY, 2018, 136 (03) :257-269

[5] Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration [J].

Chakravarthy, Usha ;

Harding, Simon P. ;

Rogers, Chris A. ;

Downes, Susan M. ;

Lotery, Andrew J. ;

Wordsworth, Sarah ;

Reeves, Barnaby C. .

OPHTHALMOLOGY, 2012, 119 (07) :1399-1411

[6] SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT [J].

Chhablani, Jay ;

Narayanan, Raja ;

Mathai, Annie ;

Yogi, Rohit ;

Stewart, Michael .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (06) :1126-1131

[7] Preclinical Investigations of Intravitreal Ziv-Aflibercept [J].

de Oliveira Dias, Joao Rafael ;

Badaro, Emmerson ;

Novais, Eduardo Amorim ;

Colicchio, Daniel ;

Denadai Chiarantin, Gabrielly Maria ;

Matioli, Mariana Mauricio ;

Verna, Carina ;

Penha, Fernando Marcondes ;

Tenorio Barros, Nilana Meza ;

Meyer, Carsten H. ;

Farah, Michel Eid ;

Rodrigues, Eduardo Buchele .

OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2014, 45 (06) :577-584

[8] VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration [J].

Dixon, James A. ;

Oliver, Scott C. N. ;

Olson, Jeffrey L. ;

Mandava, Naresh .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (10) :1573-1580

[9]

Eldeeb Mohab, 2017, Am J Ophthalmol Case Rep, V8, P58, DOI 10.1016/j.ajoc.2017.10.011

[10] Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema [J].

Ferris, Frederick L., III ;

Maguire, Maureen G. ;

Glassman, Adam R. ;

Ying, Gui-shuang ;

Martin, Daniel F. .

JAMA OPHTHALMOLOGY, 2017, 135 (02) :145-149

← 1 2 3 →